 Joseph Rosenthal
Concepts (170)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Brain Injuries, Traumatic | 4 | 2016 | 341 | 0.910 |
Why?
| | Antibodies, Bacterial | 3 | 2016 | 137 | 0.680 |
Why?
| | Brain Ischemia | 4 | 2022 | 321 | 0.590 |
Why?
| | Bacterial Vaccines | 2 | 2016 | 62 | 0.580 |
Why?
| | Bacterial Outer Membrane Proteins | 2 | 2016 | 58 | 0.570 |
Why?
| | Antigens, Bacterial | 2 | 2016 | 119 | 0.570 |
Why?
| | Fatigue | 2 | 2016 | 316 | 0.550 |
Why?
| | Neurological Rehabilitation | 1 | 2016 | 5 | 0.530 |
Why?
| | Models, Neurological | 1 | 2016 | 242 | 0.450 |
Why?
| | Vaccines, Virus-Like Particle | 1 | 2013 | 3 | 0.440 |
Why?
| | Th1 Cells | 1 | 2014 | 137 | 0.440 |
Why?
| | Stroke | 4 | 2022 | 1070 | 0.420 |
Why?
| | Seizures | 1 | 2016 | 401 | 0.410 |
Why?
| | Drug Carriers | 1 | 2013 | 119 | 0.400 |
Why?
| | Escherichia coli | 3 | 2016 | 766 | 0.390 |
Why?
| | Sports | 1 | 2014 | 225 | 0.360 |
Why?
| | Blindness, Cortical | 1 | 2011 | 5 | 0.360 |
Why?
| | Autonomic Dysreflexia | 1 | 2011 | 4 | 0.360 |
Why?
| | Quadriplegia | 1 | 2011 | 12 | 0.360 |
Why?
| | Population Surveillance | 1 | 2014 | 438 | 0.350 |
Why?
| | Athletes | 1 | 2014 | 409 | 0.340 |
Why?
| | Nanoparticles | 1 | 2013 | 375 | 0.320 |
Why?
| | Students | 1 | 2014 | 579 | 0.300 |
Why?
| | Vaccines | 1 | 2013 | 398 | 0.300 |
Why?
| | Endovascular Procedures | 2 | 2022 | 301 | 0.280 |
Why?
| | Athletic Injuries | 1 | 2014 | 510 | 0.280 |
Why?
| | Hospitalization | 1 | 2016 | 2052 | 0.260 |
Why?
| | Accidental Falls | 2 | 2016 | 169 | 0.220 |
Why?
| | Vaccines, Synthetic | 2 | 2014 | 126 | 0.220 |
Why?
| | Mechanical Thrombolysis | 1 | 2022 | 4 | 0.200 |
Why?
| | Cell Membrane | 3 | 2014 | 733 | 0.200 |
Why?
| | Arterial Occlusive Diseases | 1 | 2022 | 80 | 0.190 |
Why?
| | Thrombectomy | 4 | 2022 | 58 | 0.180 |
Why?
| | Neurologists | 1 | 2021 | 20 | 0.180 |
Why?
| | Restraint, Physical | 1 | 2021 | 67 | 0.180 |
Why?
| | Law Enforcement | 1 | 2021 | 39 | 0.180 |
Why?
| | Motor Cortex | 1 | 2020 | 58 | 0.170 |
Why?
| | Brain Injuries | 2 | 2015 | 466 | 0.170 |
Why?
| | Amyotrophic Lateral Sclerosis | 1 | 2020 | 68 | 0.170 |
Why?
| | Carotid Arteries | 1 | 2021 | 196 | 0.160 |
Why?
| | Gene Expression | 2 | 2014 | 1466 | 0.160 |
Why?
| | Physician's Role | 1 | 2021 | 206 | 0.160 |
Why?
| | Cerebrovascular Circulation | 1 | 2021 | 227 | 0.150 |
Why?
| | Mice, Inbred BALB C | 3 | 2016 | 1247 | 0.150 |
Why?
| | Bone Marrow Transplantation | 1 | 2018 | 275 | 0.140 |
Why?
| | Magnetic Resonance Imaging | 3 | 2022 | 3386 | 0.140 |
Why?
| | Epilepsy, Post-Traumatic | 1 | 2016 | 3 | 0.130 |
Why?
| | Tomography Scanners, X-Ray Computed | 1 | 2016 | 19 | 0.130 |
Why?
| | Neisseria meningitidis, Serogroup B | 1 | 2016 | 15 | 0.130 |
Why?
| | Sensation Disorders | 1 | 2016 | 32 | 0.130 |
Why?
| | Immunoglobulin Class Switching | 1 | 2016 | 19 | 0.130 |
Why?
| | Transport Vesicles | 1 | 2016 | 18 | 0.130 |
Why?
| | Blood Transfusion | 1 | 2018 | 295 | 0.130 |
Why?
| | Craniotomy | 1 | 2016 | 67 | 0.130 |
Why?
| | Tularemia | 1 | 2016 | 28 | 0.130 |
Why?
| | Francisella tularensis | 1 | 2016 | 30 | 0.130 |
Why?
| | Male | 13 | 2022 | 63512 | 0.130 |
Why?
| | Polysaccharides | 1 | 2016 | 86 | 0.130 |
Why?
| | Immunization | 2 | 2016 | 411 | 0.120 |
Why?
| | Remission Induction | 1 | 2016 | 271 | 0.120 |
Why?
| | Female | 15 | 2022 | 68551 | 0.120 |
Why?
| | International Classification of Diseases | 1 | 2016 | 122 | 0.120 |
Why?
| | Community Participation | 1 | 2016 | 124 | 0.120 |
Why?
| | Psychomotor Agitation | 1 | 2015 | 64 | 0.120 |
Why?
| | Recombinant Fusion Proteins | 2 | 2014 | 648 | 0.120 |
Why?
| | Geriatric Assessment | 1 | 2016 | 205 | 0.120 |
Why?
| | Inpatients | 2 | 2015 | 462 | 0.120 |
Why?
| | Hemolysin Proteins | 1 | 2014 | 34 | 0.120 |
Why?
| | Longitudinal Studies | 3 | 2016 | 2715 | 0.110 |
Why?
| | Vaccines, Subunit | 1 | 2014 | 48 | 0.110 |
Why?
| | Genes, Synthetic | 1 | 1994 | 15 | 0.110 |
Why?
| | Triage | 1 | 2016 | 206 | 0.110 |
Why?
| | Bungarotoxins | 1 | 1994 | 45 | 0.110 |
Why?
| | Craniocerebral Trauma | 1 | 2016 | 151 | 0.110 |
Why?
| | Humans | 20 | 2022 | 129266 | 0.110 |
Why?
| | Probiotics | 1 | 2014 | 51 | 0.110 |
Why?
| | Epitopes | 1 | 2016 | 470 | 0.110 |
Why?
| | Epidemiologic Studies | 1 | 2014 | 65 | 0.110 |
Why?
| | Adult | 8 | 2021 | 35495 | 0.110 |
Why?
| | Postural Balance | 1 | 2016 | 199 | 0.110 |
Why?
| | Immunity, Humoral | 1 | 2014 | 118 | 0.110 |
Why?
| | Biomimetics | 1 | 2013 | 42 | 0.110 |
Why?
| | Young Adult | 4 | 2018 | 12391 | 0.110 |
Why?
| | Species Specificity | 1 | 2014 | 574 | 0.110 |
Why?
| | Sleep Wake Disorders | 1 | 2016 | 251 | 0.100 |
Why?
| | Escherichia coli Proteins | 1 | 2014 | 178 | 0.100 |
Why?
| | Immunity, Cellular | 1 | 2014 | 265 | 0.100 |
Why?
| | Aged | 7 | 2022 | 22032 | 0.100 |
Why?
| | Risk Factors | 5 | 2018 | 9745 | 0.100 |
Why?
| | Middle Aged | 6 | 2022 | 31090 | 0.100 |
Why?
| | Adjuvants, Immunologic | 1 | 2013 | 221 | 0.100 |
Why?
| | Logistic Models | 1 | 2016 | 1985 | 0.090 |
Why?
| | Thrombolytic Therapy | 2 | 2022 | 137 | 0.090 |
Why?
| | Depression | 2 | 2016 | 1306 | 0.090 |
Why?
| | Schools | 1 | 2014 | 439 | 0.090 |
Why?
| | Follow-Up Studies | 2 | 2016 | 4887 | 0.090 |
Why?
| | Adolescent | 4 | 2018 | 20313 | 0.080 |
Why?
| | Biocompatible Materials | 1 | 2013 | 388 | 0.080 |
Why?
| | Treatment Outcome | 5 | 2022 | 10202 | 0.080 |
Why?
| | Time Factors | 2 | 2016 | 6543 | 0.080 |
Why?
| | Magnetic Resonance Angiography | 1 | 2011 | 234 | 0.080 |
Why?
| | Anxiety | 1 | 2015 | 962 | 0.080 |
Why?
| | Emergency Service, Hospital | 2 | 2016 | 1896 | 0.070 |
Why?
| | Radiography | 1 | 2011 | 796 | 0.070 |
Why?
| | Prognosis | 1 | 2016 | 3773 | 0.070 |
Why?
| | Canada | 2 | 2021 | 350 | 0.070 |
Why?
| | Bacteria | 1 | 2014 | 813 | 0.070 |
Why?
| | Aged, 80 and over | 4 | 2021 | 7055 | 0.070 |
Why?
| | United States | 4 | 2021 | 13826 | 0.070 |
Why?
| | Brain Concussion | 1 | 2014 | 549 | 0.070 |
Why?
| | Rehabilitation Centers | 2 | 2015 | 37 | 0.060 |
Why?
| | Prospective Studies | 4 | 2021 | 7123 | 0.060 |
Why?
| | Mice | 3 | 2016 | 16915 | 0.050 |
Why?
| | Animals | 5 | 2016 | 35309 | 0.050 |
Why?
| | Retrospective Studies | 4 | 2022 | 14461 | 0.050 |
Why?
| | Age Factors | 2 | 2021 | 3140 | 0.050 |
Why?
| | Reperfusion | 1 | 2021 | 38 | 0.050 |
Why?
| | Incidence | 2 | 2018 | 2636 | 0.040 |
Why?
| | Cerebral Hemorrhage | 1 | 2021 | 105 | 0.040 |
Why?
| | Neck | 1 | 2021 | 94 | 0.040 |
Why?
| | Tissue Plasminogen Activator | 1 | 2021 | 222 | 0.040 |
Why?
| | Fibrinolytic Agents | 1 | 2022 | 262 | 0.040 |
Why?
| | Transfusion Reaction | 1 | 2018 | 43 | 0.040 |
Why?
| | Brain | 1 | 2011 | 2669 | 0.040 |
Why?
| | Transplantation, Homologous | 1 | 2018 | 400 | 0.030 |
Why?
| | Cohort Studies | 2 | 2018 | 5409 | 0.030 |
Why?
| | Age of Onset | 1 | 2018 | 496 | 0.030 |
Why?
| | Hematologic Neoplasms | 1 | 2018 | 140 | 0.030 |
Why?
| | O Antigens | 1 | 2016 | 8 | 0.030 |
Why?
| | Antigen-Antibody Reactions | 1 | 2016 | 52 | 0.030 |
Why?
| | Graft vs Host Disease | 1 | 2018 | 240 | 0.030 |
Why?
| | Glycosylation | 1 | 2016 | 152 | 0.030 |
Why?
| | Statistics, Nonparametric | 1 | 2016 | 420 | 0.030 |
Why?
| | Trauma Severity Indices | 1 | 2015 | 104 | 0.030 |
Why?
| | Chromatography, DEAE-Cellulose | 1 | 1994 | 13 | 0.030 |
Why?
| | Electric Organ | 1 | 1994 | 8 | 0.030 |
Why?
| | Torpedo | 1 | 1994 | 10 | 0.030 |
Why?
| | Snakes | 1 | 1994 | 20 | 0.030 |
Why?
| | Factor Xa | 1 | 1994 | 32 | 0.030 |
Why?
| | Survival Rate | 1 | 2018 | 1869 | 0.030 |
Why?
| | Bioengineering | 1 | 2014 | 19 | 0.030 |
Why?
| | Aspartic Acid | 1 | 1994 | 80 | 0.030 |
Why?
| | Oligodeoxyribonucleotides | 1 | 1994 | 140 | 0.030 |
Why?
| | Alanine | 1 | 1994 | 142 | 0.030 |
Why?
| | Trauma Centers | 1 | 2016 | 402 | 0.030 |
Why?
| | Hematopoietic Stem Cell Transplantation | 1 | 2018 | 572 | 0.030 |
Why?
| | Injury Severity Score | 1 | 2015 | 509 | 0.030 |
Why?
| | Point Mutation | 1 | 1994 | 224 | 0.030 |
Why?
| | Mutagenesis, Site-Directed | 1 | 1994 | 361 | 0.030 |
Why?
| | Protein Structure, Secondary | 1 | 1994 | 340 | 0.030 |
Why?
| | Cloning, Molecular | 1 | 1994 | 525 | 0.030 |
Why?
| | Linear Models | 1 | 2015 | 819 | 0.030 |
Why?
| | Biological Transport | 1 | 2014 | 404 | 0.030 |
Why?
| | Protein Folding | 1 | 1994 | 264 | 0.020 |
Why?
| | Pilot Projects | 1 | 2016 | 1584 | 0.020 |
Why?
| | Cognitive Dysfunction | 1 | 2015 | 346 | 0.020 |
Why?
| | Recombinant Proteins | 1 | 1994 | 1304 | 0.020 |
Why?
| | Exercise Therapy | 1 | 2014 | 412 | 0.020 |
Why?
| | Base Sequence | 1 | 1994 | 2146 | 0.020 |
Why?
| | Amino Acid Sequence | 1 | 1994 | 2056 | 0.020 |
Why?
| | Molecular Sequence Data | 1 | 1994 | 2835 | 0.020 |
Why?
| | Prevalence | 1 | 2015 | 2553 | 0.020 |
Why?
| | Models, Molecular | 1 | 1994 | 1487 | 0.020 |
Why?
| | Practice Guidelines as Topic | 1 | 2016 | 1497 | 0.020 |
Why?
| | Vaccination | 1 | 2016 | 1347 | 0.020 |
Why?
| | Infant, Newborn | 1 | 2018 | 5736 | 0.020 |
Why?
| | Risk Assessment | 1 | 2016 | 3232 | 0.020 |
Why?
| | Infant | 1 | 2018 | 8975 | 0.010 |
Why?
| | Child, Preschool | 1 | 2018 | 10459 | 0.010 |
Why?
| | Child | 1 | 2018 | 20785 | 0.010 |
Why?
|
|
Rosenthal's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
|